Hi, today we are going to talk about Pfizer and its current landscape.
Pfizer is poised to receive increasing attention from the market as relevant events are taking place. The American multinational pharmaceutical has unveiled that is raising its quarterly dividend from $0.36 to $0.38 per share, a 6% surge that combined with the FDA approval of its new prostate cancer drug can help Pfizer change its currently bad momentum. However, the Lower Drug Costs Now Act can hit the company if it becomes law, despite the lack of support from the Trump administration and Senate, an eventual approval would throw a bearish sentiment over the sector.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Pfizer is poised to receive increasing attention from the market as relevant events are taking place. The American multinational pharmaceutical has unveiled that is raising its quarterly dividend from $0.36 to $0.38 per share, a 6% surge that combined with the FDA approval of its new prostate cancer drug can help Pfizer change its currently bad momentum. However, the Lower Drug Costs Now Act can hit the company if it becomes law, despite the lack of support from the Trump administration and Senate, an eventual approval would throw a bearish sentiment over the sector.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Igor Silva · análise técnica e sistemas quantitativos
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.
Igor Silva · análise técnica e sistemas quantitativos
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.